Advanced Cardiovascular Life Support Exam C

The ACLS written exam doesn't care how many years you've been a nurse. Practically speaking, it doesn't care that you've run real codes. It cares about one thing: whether you can pick the right answer when the scenario looks almost right but isn't.

I've watched experienced ICU nurses fail this test. Not because they didn't know the algorithms — they did. Think about it: they failed because they overthought. They second-guessed. They picked the "clinical judgment" answer instead of the "guideline" answer Small thing, real impact..

Here's what nobody tells you in the prep course: the exam isn't testing your clinical wisdom. It's testing your ability to apply the 2020 AHA guidelines exactly as written, in the exact sequence they're written, without deviation That alone is useful..

What Is the ACLS Exam C

Exam C is one of the current written test versions used by the American Heart Association for Advanced Cardiovascular Life Support certification. Same content domain as Exam A and Exam B — just different questions, different order, same passing standard And that's really what it comes down to..

Fifty questions. Because of that, multiple choice. Eighty-four percent to pass. That's forty-two correct answers. You get two attempts per testing session before you have to remediate Most people skip this — try not to..

The questions pull from every algorithm: cardiac arrest, bradycardia, tachycardia, acute coronary syndrome, stroke, post-cardiac arrest care, and the systematic approach (BLS, primary, secondary assessment). Pharmacology is woven throughout — doses, routes, timing, contraindications Worth knowing..

What makes Exam C feel different? Nothing. It's the same blueprint. The variation is purely psychometric. But if you're retesting after failing A or B, the questions will be unfamiliar. That's the point.

The Format You'll Actually See

Scenario-based stems. Practically speaking, three to five sentences. Patient presentation, rhythm strip description or image, vital signs, sometimes a brief history. Then: "What is the next best action?" or "Which medication and dose?" or "What is the most likely cause?

You'll see rhythm strips. Not full 12-leads. Practically speaking, lead II strips mostly. You need to identify: sinus rhythm, sinus brady, sinus tachy, SVT, a-fib with RVR, a-flutter, VT (monomorphic and polymorphic), VF, asystole, PEA, and the various heart blocks. Day to day, fast. Cold Small thing, real impact..

No reference cards during the written portion. You either know the doses or you don't Most people skip this — try not to..

Why This Exam Trips Up Smart People

The guidelines are rigid. Now, clinical practice is fluid. That tension is where people lose points Small thing, real impact..

In real life, you might give amiodarone before the third shock because the patient keeps going back into VF and you're thinking ahead. On the exam? The algorithm says: shock, CPR, epinephrine, shock, CPR, amiodarone. Deviation = wrong answer.

Another trap: "reasonable" vs. "recommended.Here's the thing — " The guidelines use specific language. Class I = recommended. Class IIa = reasonable. Class IIb = may be considered. Now, class III = not recommended/harmful. The exam tests whether you know which intervention carries which classification.

Example: transcutaneous pacing for symptomatic bradycardia. Class I. That's why atropine first? Also Class I. But the sequence matters. Atropine 1 mg IV, repeat every 3-5 minutes to 3 mg max. So if no response — then pacing. Because of that, skip atropine in high-degree block (Mobitz II, third-degree). Worth adding: go straight to pacing. That distinction appears on every version of this test.

The "Real World" Bias

You've seen things work that aren't in the guidelines. Maybe your ED pushes calcium for wide-complex tachycardia of uncertain etiology. Maybe your ICU uses push-dose pressors before the algorithm says so.

Leave it at the door. Plus, the correct answer is the guideline answer. Also, the exam is a closed system. Period.

I've seen paramedics with twenty years' experience argue with the answer key. On the flip side, your system doesn't write the test. "But in my system we—" Stop. The AHA does.

How the Algorithms Actually Work on the Test

Every algorithm question follows a pattern: identify the rhythm → assess stability → intervene per pathway. Miss step one, and everything after is guesswork Simple, but easy to overlook..

Cardiac Arrest: The Two-Track System

VF/pVT track and asystole/PEA track. They diverge after the first shock decision That's the part that actually makes a difference..

VF/pVT:

• Shock immediately (biphasic: manufacturer recommendation, typically 120-200 J)
• Resume CPR immediately — 2 minutes
• Epinephrine 1 mg IV/IO every 3-5 minutes (after second shock)
• Amiodarone 300 mg IV/IO (after third shock), then 150 mg if needed
• Consider magnesium for torsades
• Consider lidocaine if amiodarone unavailable
• Treat reversible causes (H's and T's) throughout

Asystole/PEA:

• No shock
• CPR 2 minutes
• Epinephrine 1 mg IV/IO every 3-5 minutes (as soon as IV/IO access)
• Treat reversible causes aggressively — this is where PEA survives or dies
• Consider pacing for asystole? No. Class III. Don't do it.

The exam loves asking: "Patient in PEA. CPR in progress. IV access obtained. Next action?That said, " Answer: Epinephrine 1 mg IV. Even so, not "check rhythm. " Not "intubate." Epinephrine. Every 3-5 minutes.

Bradycardia: The Stability Fork

Symptomatic? Hypotension, altered mental status, signs of shock, ischemic chest discomfort, acute heart failure Not complicated — just consistent..

Unstable:

• Atropine 1 mg IV (repeat q3-5 min, max 3 mg)
• If no response → transcutaneous pacing (Class I)
• If pacing unavailable/delayed → dopamine 2-20 mcg/kg/min or epinephrine 2-10 mcg/min infusion

Stable:

• Observe, monitor, identify cause
• Atropine only if symptomatic and not high-degree block

High-degree block (Mobitz II, third-degree) = atropine often ineffective. Pacing first. This shows up constantly Worth keeping that in mind. And it works..

Tachycardia: Wide vs. Narrow, Stable vs. Unstable

Unstable with a pulse = synchronized cardioversion. Worth adding: always. Sedate if conscious but don't delay.

Narrow complex regular (SVT):

• Vagal maneuvers → adenosine 6 mg rapid IV push → adenosine 12 mg → adenosine 12 mg
• If refractory: consider cardioversion or antiarrhythmic infusion

Wide complex regular:

• If monomorphic VT and stable: adenosine may terminate (diagnostic/therapeutic) — but procainamide, amiodarone, or sotalol infusion preferred
• If polymorphic VT: treat as unstable → shock (unsynchronized if deteriorating)
• If irregular wide: a-fib with aberrancy vs. pre-excitation vs. torsades. Treat per underlying rhythm.

The exam tests: "Wide complex tachycardia, regular, hemodynamically stable. Next step?Practically speaking, " Procainamide infusion (20-50 mg/min) or amiodarone 150 mg over 10 min. In practice, not adenosine first — though adenosine is acceptable for diagnostic purposes in monomorphic VT. Know the nuance Worth keeping that in mind..

Acute Coronary Syndrome

Time is muscle. The algorithm:

• Oxygen if SpO2 < 90%
• Aspirin 162-325 mg chewed
• Nitroglycerin sublingual (avoid if RV infarct suspected — check V4R)
• Morphine if pain unrelieved (Class IIb now — use cautiously)
• Fibrinolytic vs

You'll probably want to bookmark this section.

The next tier of interventions targets reperfusion and secondary prevention.

Reperfusion strategy

• ST‑elevation MI (STEMI): Activate the cardiac catheterization laboratory immediately if primary PCI is available within 90 minutes of first medical contact. If PCI will be delayed >120 minutes, administer a fibrinolytic regimen (alteplase, reteplase, or tenecteplase) unless a contraindication exists.
• Non‑ST‑elevation ACS (NSTEMI/UA): Early invasive strategy is recommended for high‑risk patients (elevated cardiac biomarkers, hemodynamic instability, recurrent ischemia, or arrhythmias). Early risk stratification (TIMI or GRACE score) guides timing of angiography, typically within 24–48 hours.

Adjunctive pharmacology

• Dual antiplatelet therapy: Aspirin (162–325 mg chewed) plus a P2Y12 inhibitor (clopidogrel 600 mg loading, ticagrelor 180 mg loading, or prasugrel 60 mg loading) for at least 12 months in STEMI patients undergoing PCI, and for 6–12 months in NSTEMI/UA patients with high ischemic risk.
• Anticoagulation: Unfractionated heparin (weight‑based bolus) or a low‑molecular‑weight heparin (enoxaparin 1 mg/kg subcutaneously every 12 hours) during the acute phase, transitioning to oral agents (e.g., rivaroxaban 2.5 mg twice daily) after discharge when indicated.
• Beta‑blocker: Metoprolol 5 mg IV every 5 minutes (max 15 mg) or oral bisoprolol 5 mg daily if no contraindications (e.g., heart block, severe bradycardia, decompensated HF). Initiate early to reduce myocardial oxygen demand.
• Statin therapy: High‑intensity statin (atorvastatin 80 mg or rosuvastatin 20 mg) initiated immediately, irrespective of baseline LDL, to stabilize the plaque and reduce inflammation.

Post‑discharge pathway

• Transition to oral antiplatelet and anticoagulant regimens as above.
• Enroll in cardiac rehabilitation within 24–48 hours of discharge to improve functional status, medication adherence, and risk‑factor control.
• Schedule follow‑up with cardiology within 1–2 weeks for repeat labs, ECG, and assessment of left‑ventricular function.

Pericarditis

The hallmark is chest pain that improves when leaning forward and worsens when supine.

• First‑line: NSAIDs (ibuprofen 600 mg PO q6 h or naproxen 500 mg PO bid) plus colchicine 0.6 mg PO daily (adjusted for renal function).
• If NSAIDs are contraindicated or ineffective: Consider corticosteroids (prednisone 30–40 mg daily, taper over 2–3 weeks) or intravenous immunoglobulin for refractory cases.
• Complications: Cardiac tamponade → emergent pericardiocentesis; constrictive pericarditis → long‑term anti‑inflammatory therapy and, if chronic, surgical pericardiectomy.

Acute Heart Failure (AHF)

• Oxygen to maintain SpO₂ > 94 % (or 88–92 % in COPD).
• Diuresis: Loop diuretic (furosemide 20–40 mg IV bolus, repeat as needed) plus consider metolazone for diuretic resistance.
• Vasodilators (nitrates, nesiritide) for afterload reduction in patients without hypotension.
• Inotropes for cardiogenic shock: dobutamine, milrinone, or levosimendan; transition to oral agents once hemodynamically stable.
• Monitoring: Serial weights, daily intake‑output, electrolytes, and renal function.

Cardiogenic Shock

• Immediate actions: Maintain MAP ≥ 65 mmHg with fluid resuscitation (if hypovolemic) or vasopressors (norepinephrine 0.05–0.2 µg/kg/min) and inotropes (dobutamine 2–20 µg/kg/min, milrinone 0.05–0.2 µg/kg/min).
• Device support: Intra‑aortic balloon pump (IABP) or, in refractory cases, VA‑ECMO for temporary circulatory support.
• Targeted therapy: Identify underlying etiology (MI

or myocarditis) and initiate targeted therapy (e.In real terms, g. Think about it: , emergent reperfusion for MI, surgical repair for valvular pathology). - Inotropic and vasopressor optimization: Titrate agents to restore perfusion while avoiding excessive tachycardia or hypertension. Consider milrinone or levosimendan in patients with concomitant ventricular arrhythmias.
And - Mechanical circulatory support escalation: In cases unresponsive to pharmacological therapy, early transition to durable devices (e. g., Impella, extracorporeal membrane oxygenation) may be lifesaving while awaiting recovery or transplantation.

Special Considerations in Complex Cases

Renal replacement therapy: Initiate hemodialysis or continuous renal replacement therapy (CRRT) in cardiogenic shock with severe acute kidney injury, balancing fluid removal and electrolyte management.
Anticoagulation strategy: Use unfractionated heparin (target aPTT 60–80 seconds) in shock states with high thrombotic risk; avoid low-molecular-weight heparin in renal failure.
Electrolyte and metabolic management: Correct hypokalemia, hypomagnesemia, or acidosis aggressively, as these abnormalities exacerbate arrhythmogenesis and myocardial depression It's one of those things that adds up..

Conclusion

Effective management of acute cardiac emergencies demands a protocol-driven, time-sensitive approach built for the specific pathophysiology of each condition. Early initiation of reperfusion in ACS, prompt anti-inflammatory therapy in pericarditis, and aggressive hemodynamic stabilization in AHF and cardiogenic shock are critical to reducing mortality. Equally important is seamless transition to oral agents, structured discharge planning, and strong follow-up to address long-term risk factors and prevent readmission It's one of those things that adds up..

A multidisciplinary team—including cardiologists, critical care specialists, pharmacists, and rehabilitation professionals—plays an integral role in translating acute interventions into long‑term health. Pharmacists conduct comprehensive medication reconciliation, ensuring seamless transition from intravenous to oral agents while identifying potential drug‑drug interactions and optimizing dosing in the context of residual renal dysfunction. Rehabilitation specialists design individualized exercise and nutrition programs that address deconditioning, improve functional capacity, and reinforce lifestyle modifications such as sodium restriction and smoking cessation. Nursing staff provide education on symptom recognition, medication adherence, and when to seek urgent care, thereby empowering patients to become active participants in their recovery.

Beyond the bedside, system‑level strategies reinforce the gains achieved during hospitalization. Structured heart‑failure clinics, scheduled cardiology follow‑up within 7–10 days, and coordinated tele‑monitoring platforms enable early detection of decompensation, allowing timely adjustments before overt clinical deterioration. Community resources—such as support groups, financial counseling, and home‑health services—address psychosocial barriers that frequently undermine self‑care and medication compliance But it adds up..

Conclusion
The management of acute cardiac emergencies is a continuum that spans rapid diagnosis, evidence‑based emergency therapy, vigilant monitoring, and a seamless bridge to outpatient stability. Success hinges not only on the timely application of guideline‑driven treatments but also on the coordinated effort of a diverse healthcare team that tailors each intervention to the patient’s evolving clinical picture. By integrating swift reperfusion, hemodynamic optimization, targeted pharmacologic and device‑based support, and reliable post‑discharge planning, clinicians can markedly improve survival, reduce repeat hospitalizations, and grow lasting cardiovascular health. Continuous quality improvement, adherence to clinical pathways, and a patient‑centered mindset remain the cornerstones of achieving these outcomes.